Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Denali Therapeutics (DNLI) EPS (Weighted Average and Diluted) (2018 - 2026)

Denali Therapeutics has reported EPS (Weighted Average and Diluted) over the past 8 years, most recently at -$0.73 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 7.35% to -$0.73 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.97 through Dec 2025, down 15.12% year-over-year, with the annual reading at -$2.97 for FY2025, 15.56% down from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.73 for Q4 2025 at Denali Therapeutics, up from -$0.74 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $1.3 in Q2 2023 and troughed at -$0.87 in Q4 2023.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.68 (2021), against an average of -$0.58.
  • Year-over-year, EPS (Weighted Average and Diluted) skyrocketed 370.83% in 2023 and then plummeted 145.38% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.62 in 2021, then decreased by 20.97% to -$0.75 in 2022, then decreased by 16.0% to -$0.87 in 2023, then increased by 21.84% to -$0.68 in 2024, then decreased by 7.35% to -$0.73 in 2025.
  • Per Business Quant, the three most recent readings for DNLI's EPS (Weighted Average and Diluted) are -$0.73 (Q4 2025), -$0.74 (Q3 2025), and -$0.72 (Q2 2025).